Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma

Research output: Contribution to journalLetterResearchpeer-review

Documents

  • Fulltext

    Accepted author manuscript, 658 KB, PDF document

This figure presents a comparison of molecular imaging of the translocator protein (TSPO) and contrast-enhanced MRI in 2 patients with tumefactive multiple sclerosis and glioblastoma, respectively. In the case of the tumefactive multiple sclerosis patient, TSPO uptake is primarily located centrally, while in the glioblastoma patient, TSPO uptake is predominantly situated peripherally to the central necrotic area. These findings suggest that TSPO imaging could be a noninvasive imaging technique for distinguishing between these 2 diagnoses.

Original languageEnglish
JournalClinical Nuclear Medicine
Volume48
Issue number8
Pages (from-to)E403-E404
Number of pages2
ISSN0363-9762
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.

    Research areas

  • glioma, MRI, SPECT, translocator protein, tumefactive MS

ID: 363282607